-The Times of India NEW DELHI: In what is being seen as an attempt to delay launch of low priced generic medicines, multinational drug makers have asked the government to create a registry providing information about all drug applications pending manufacturing and marketing approval. The proposal, if accepted by the government, will help ‘big pharma’ pre-emptively challenge generic drug makers in court for allegedly infringing upon their patents and in turn blocking...

-The Times of India NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting such medicines from price control, derailing plans to make these drugs affordable. The health ministry discussed price capping and invoking compulsory licence for these “exorbitantly” priced “orphan drugs” at a meeting on January 3, the day when DoP...

-Livemint.com Govt plans to?help firms revamp manufacturing units,?refurbish machinery,?ensure subsidized power in bid to produce drugs such as penicillin at competitive rates New Delhi: The Department of Pharmaceuticals (DoP), during a meeting on Wednesday, urged pharma companies to strive for self-sufficiency in critical drugs like penicillin, rifampicin and insulin, in a sign of government concern over India’s dependence on Chinese imports. A large number of so-called active pharmaceutical ingredients (APIs), or bulk drugs,...

-TheWire.in The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog and the Department of Pharmaceuticals (DoP) may be working in an opposing direction. Documents between October 2016 and April 2017 show the intention of various government arms to...

-The Times of India NEW DELHI: The government has invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months. Amid reports that several manufacturers, including Abbott and Medtronic, are seeking to withdraw premium, high-priced stents from the Indian market on account of the price cap imposed by National Pharmaceutical Pricing Authority (NPPA), the government has directed companies to maintain production,...